 Benzimidazoles
"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 3 | 3 | | 2010 | 2 | 0 | 2 | | 2011 | 2 | 3 | 5 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 3 | 5 | | 2014 | 7 | 4 | 11 | | 2015 | 4 | 3 | 7 | | 2016 | 4 | 0 | 4 | | 2017 | 4 | 1 | 5 | | 2018 | 10 | 4 | 14 | | 2019 | 5 | 2 | 7 | | 2020 | 2 | 4 | 6 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 2 | 4 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 Apr 30; 80(4):744-751.
-
Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, Bowles DW, Gadgeel SM, Mihalcioiu C, Papadopoulos KP, Diamond EL, Sturtz KB, Feng G, Drescher SK, Reddy MB, Sengupta B, Maity AK, Brown SA, Singh A, Brown EN, Baer BR, Wong J, Mou TC, Wu WI, Kahn DR, Gadal S, Rosen N, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM. A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation. Cancer Discov. 2024 Sep 04; 14(9):1599-1611.
-
Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. Clin Cancer Res. 2024 Sep 03; 30(17):3768-3778.
-
Jonas MM, Romero R, Rosenthal P, Lin CH, Verucchi G, Wen J, Balistreri WF, Whitworth S, Bansal S, Leung DH, Narkewicz MR, Gonzalez-Peralta RP, Mangia A, Karnsakul W, Rao GS, Shao J, de Jong J, Parhy B, Osinusi A, Kersey K, Murray KF, Sokal EM, Schwarz KB. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
Ghosh S, Devereaux MW, Orlicky DJ, Sokol RJ. Pharmacologic inhibition of HNF4a prevents parenteral nutrition associated cholestasis in mice. Sci Rep. 2023 05 12; 13(1):7752.
-
Nashaat S, Henen MA, El-Messery SM, Eisa H. New Benzimidazoles Targeting Breast Cancer: Synthesis, Pin1 Inhibition, 2D NMR Binding, and Computational Studies. Molecules. 2022 Aug 17; 27(16).
-
Calello DP, Aldy K, Jefri M, Nguyen TT, Krotulski A, Logan B, Brent J, Wax P, Walton S, Manini AF. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila). 2022 09; 60(9):1067-1069.
-
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 02; 40(1):115-123.
-
Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, Gonzalez-Peralta RP, Hierro L, Leung DH, Ling SC, Lobzin Y, Lobritto S, Mizuochi T, Narkewicz MR, Sabharwal V, Wen J, Kei Lon H, Marcinak J, Topp A, Tripathi R, Sokal E. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 07; 74(1):19-27.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|